Reaction Details Report a problem with these data
Target
Serine/threonine-protein kinase SIK2
Ligand
BDBM632973
Substrate
n/a
Meas. Tech.
Inhibition of SIK; Abl and Src Kinases by Other Kinase Inhibitor
IC50
<10.00±n/a nM
Citation
 SENNHENN, P; BISSINGER, S; LOFERER, H; BANCROFT, D; MICHELS, T; KHANDELWAL, N HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF US Patent  US20230348453 Publication Date 11/2/2023 
Target
Name:
Serine/threonine-protein kinase SIK2
Synonyms:
KIAA0781 | QIK | SIK2 | SIK2_HUMAN | SNF1LK2 | Salt-inducible kinase 2 (SIK2) | Serine/threonine-protein kinase SIK2
Type:
Protein
Mol. Mass.:
103906.53
Organism:
Homo sapiens (Human)
Description:
n/a
Residue:
926
Sequence:
MVMADGPRHLQRGPVRVGFYDIEGTLGKGNFAVVKLGRHRITKTEVAIKIIDKSQLDAVNLEKIYREVQIMKMLDHPHIIKLYQVMETKSMLYLVTEYAKNGEIFDYLANHGRLNESEARRKFWQILSAVDYCHGRKIVHRDLKAENLLLDNNMNIKIADFGFGNFFKSGELLATWCGSPPYAAPEVFEGQQYEGPQLDIWSMGVVLYVLVCGALPFDGPTLPILRQRVLEGRFRIPYFMSEDCEHLIRRMLVLDPSKRLTIAQIKEHKWMLIEVPVQRPVLYPQEQENEPSIGEFNEQVLRLMHSLGIDQQKTIESLQNKSYNHFAAIYFLLVERLKSHRSSFPVEQRLDGRQRRPSTIAEQTVAKAQTVGLPVTMHSPNMRLLRSALLPQASNVEAFSFPASGCQAEAAFMEEECVDTPKVNGCLLDPVPPVLVRKGCQSLPSNMMETSIDEGLETEGEAEEDPAHAFEAFQSTRSGQRRHTLSEVTNQLVVMPGAGKIFSMNDSPSLDSVDSEYDMGSVQRDLNFLEDNPSLKDIMLANQPSPRMTSPFISLRPTNPAMQALSSQKREVHNRSPVSFREGRRASDTSLTQGIVAFRQHLQNLARTKGILELNKVQLLYEQIGPEADPNLAPAAPQLQDLASSCPQEEVSQQQESVSTLPASVHPQLSPRQSLETQYLQHRLQKPSLLSKAQNTCQLYCKEPPRSLEQQLQEHRLQQKRLFLQKQSQLQAYFNQMQIAESSYPQPSQQLPLPRQETPPPSQQAPPFSLTQPLSPVLEPSSEQMQYSPFLSQYQEMQLQPLPSTSGPRAAPPLPTQLQQQQPPPPPPPPPPRQPGAAPAPLQFSYQTCELPSAASPAPDYPTPCQYPVDGAQQSDLTGPDCPRSPGLQEAPSSYDPLALSELPGLFDCEMLDAVDPQHNGYVLVN
  
Inhibitor
Name:
BDBM632973
Synonyms:
N-(2-chloro-4-(fluoromethyl)thiophen- 3-yl)-2-((2-methyl-6-(4-methyl-1,4- diazepan-1-yl)pyrimidin-4- yl)amino)thiazole-5-carboxamide | US20230348453, Compound E11
Type:
Small organic molecule
Emp. Form.:
C20H23ClFN7OS2
Mol. Mass.:
496.024
SMILES:
CN1CCCN(CC1)c1cc(Nc2ncc(s2)C(=O)Nc2c(CF)csc2Cl)nc(C)n1
Structure:
Search PDB for entries with ligand similarity: